Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study

Clinical Drug Investigation

Volumn 35, Issue 10, 2015, Pages 665-673

  Han, Xue ^a,b   Jiang, Kui ^a   Wang, Bangmao ^a   Zhou, Lu ^a   Chen, Xin ^a   Li, Shu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Department of Otolaryngology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

REBAMIPIDE; TRANSCRIPTION FACTOR CDX2; TREFOIL FACTOR 3; TREFOIL PEPTIDE; UNCLASSIFIED DRUG; ALANINE; CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; PEPTIDE; QUINOLONE DERIVATIVE; TFF3 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL INFILTRATION; CHRONIC GASTRITIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GASTRIC MUCOSA; GASTRIC MUCOSAL LESION; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE METAPLASIA; LIFESTYLE MODIFICATION; LOW GRADE INTRAEPITHELIAL NEOPLASIA; MAJOR CLINICAL STUDY; MALE; MODIFIED LANZA SCORING; MONONUCLEAR CELL; NEOPLASM; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH LESION; TREATMENT DURATION; TREATMENT OUTCOME; UPDATED SYDNEY SYSTEM SCORE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GASTRITIS; HELICOBACTER INFECTIONS; METABOLISM; METAPLASIA; MIDDLE AGED; PATHOLOGY; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

ALANINE; DISEASE PROGRESSION; FEMALE; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HOMEODOMAIN PROTEINS; HUMANS; MALE; METAPLASIA; MIDDLE AGED; PEPTIDES; PRECANCEROUS CONDITIONS; QUINOLONES; STOMACH NEOPLASMS;

EID: 84942505981     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-015-0329-z     Document Type: Article

References (35)

1. Chang CS, Chen WN, Lin HH, Wu CC, Wang CJ. Increased oxidative DNA damage, inducible nitric oxide synthase, nuclear factor kappaB expression and enhanced antiapoptosis-related proteins in Helicobacter pylori-infected non-cardiac gastric adenocarcinoma. World J Gastroenterol. 2004;10:2232–40.
2. Farinati F, Cardin R, Degan P, Rugge M, Mario FD, Bonvicini P, et al. Oxidative DNA damage accumulation in gastric carcinogenesis. Gut. 1998;42:351–6.
3. Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, et al. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002;16:1449–56.
4. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut. 2007;56:772–81.
5. Rugge M, Capelle LG, Cappellesso R, Nitti D, Kuipers EJ. Precancerous lesions in the stomach: from biology to clinical patient management. Best Pract Res Clin Gastroenterol. 2013;27:205–23.
6. Yakirevich E, Resnick MB. Pathology of gastric cancer and its precursor lesions. Gastroenterol Clin N Am. 2013;42:261–84.
7. Almeida R, Silva E, Santos-Silva F, Silberg DG, Wang J, De Bolos C, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol. 2003;199:36–40.
8. Bai YQ, Yamamoto H, Akiyama Y, Tanaka H, Takizawa T, Koike M, et al. Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach. Cancer Lett. 2002;176:47–55.
9. Bornschein J, Wex T, Peitz U, Kuester D, Roessner A, Malfertheiner P. The combined presence of H. pylori infection and gastro-oesophageal reflux disease leads to an up-regulation of CDX2 gene expression in antrum and cardia. J Clin Pathol. 2009;62:254–9.
10. Xiao ZY, Ru Y, Sun JT, Gao SG, Wang YF, Wang LD, et al. Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis. Asian Pac J Cancer Prev. 2012;13:247–50.
11. Shiotani A, Iishi H, Uedo N, Ishihara R, Ishiguro S, Tatsuta M, et al. Helicobacter pylori-induced atrophic gastritis progressing to gastric cancer exhibits sonic hedgehog loss and aberrant CDX2 expression. Aliment Pharmacol Ther. 2006;24(Suppl 4):71–80.
12. Mutoh H, Sakurai S, Satoh K, Tamada K, Kita H, Osawa H, et al. Development of gastric carcinoma from intestinal metaplasia in Cdx2-transgenic mice. Cancer Res. 2004;64:7740–7.
13. Huang Z, Zhang X, Lu H, Wu L, Wang D, Zhang Q, et al. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China. BMC Gastroenterol. 2014;14:74.
14. Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 2011;141(837–45):e1–7.
15. Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci. 2001;46:2277–84.
16. Sakurai K, Sasabe H, Koga T, Konishi T. Mechanism of hydroxyl radical scavenging by rebamipide: identification of mono-hydroxylated rebamipide as a major reaction product. Free Radic Res. 2004;38:487–94.
17. Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, et al. Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci. 2009;54:1500–7.
18. Qi Z, Jie L, Haixia C, Xiaoying Z. Effect of rebamipide on quality of peptic ulcer healing in rat. Dig Dis Sci. 2009;54:1876–83.
19. Du Y, Bai Y, Xie P, Fang J, Wang X, Hou X, et al. Chronic gastritis in China: a national multi-center survey. BMC Gastroenterol. 2014;14:21.
20. Di Rienzo TA, D’Angelo G, Ojetti V, Campanale MC, Tortora A, Cesario V, et al. 13C-Urea breath test for the diagnosis of Helicobacter pylori infection. Eur Rev Med Pharmacol Sci. 2013;17(Suppl 2):51–8.
21. Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998;43:83S–9S.
22. Lanza FL, Royer GL Jr, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med. 1980;303:136–8.
23. Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N. An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci. 2008;53:2896–903.
24. Sakaki N, Kozawa H, Egawa N, Tu Y, Sanaka M. Ten-year prospective follow-up study on the relationship between Helicobacter pylori infection and progression of atrophic gastritis, particularly assessed by endoscopic findings. Aliment Pharmacol Ther. 2002;16(Suppl 2):198–203.
25. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter. 2001;6:294–9.
26. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.
27. Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002;2:28–37.
28. Walker MM. Is intestinal metaplasia of the stomach reversible? Gut. 2003;52:1–4.
29. Cheung TK, Xia HH, Wong BC. Helicobacter pylori eradication for gastric cancer prevention. J Gastroenterol. 2007;42(Suppl 17):10–5.
30. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50(Suppl 1):S3–11.
31. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S–8S.
32. Nishizawa T, Suzuki H, Nakagawa I, Minegishi Y, Masaoka T, Iwasaki E, et al. Rebamipide-promoted restoration of gastric mucosal sonic hedgehog expression after early Helicobacter pylori eradication. Digestion. 2009;79:259–62.
33. Kinjo N, Kawanaka H, Akahoshi T, Yamaguchi S, Yoshida D, Anegawa G, et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol Gastrointest Liver Physiol. 2008;295:G1016–24.
34. Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202–9.
35. Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, et al. Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol. 2002;197:582–8.